Shilpa Medicare Ltd
NSE:SHILPAMED
Operating Margin
Shilpa Medicare Ltd
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| IN |
|
Shilpa Medicare Ltd
NSE:SHILPAMED
|
96.2B INR |
16%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
765.4B USD |
40%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
373.4B USD |
26%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2.2T DKK |
45%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
209.1B CHF |
33%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
188.8B CHF |
33%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
167.7B GBP |
24%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
203.7B USD |
34%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
11%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
138.7B USD |
27%
|
Shilpa Medicare Ltd
Glance View
Shilpa Medicare Ltd. engages in the manufacturing of pharmaceutical product and wind power generation. The company is headquartered in Raichur, Karnataka. The firm is engaged in manufacturing active pharmaceutical ingredients (APIs), formulation and development service. The company is focused on new drug delivery systems, peptides/biotech products and specialty chemicals. The Company’s product range include oncology and non-oncology APIs, oncology formulations, biosimilars, ophthalmic, oral dissolving films, biochemical diagnostics, organic intermediates, pilot and production scales and transdermal patches. The company supplies oncology/non-oncology APIs and intermediates. Its oncology APIs products include Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various regulated markets including USA, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its non-oncology APIs products include Ambroxol (Mucolytic agent) in Europe and Tranexmic Acid and Ursodeoxycholic acid in India.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Shilpa Medicare Ltd's most recent financial statements, the company has Operating Margin of 15.9%.
You don't have any saved screeners yet